MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
19 déc. 2019 12h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
11 déc. 2019 10h00 HE
|
MacroGenics, Inc.
Rockville, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
09 déc. 2019 15h05 HE
|
MacroGenics, Inc.
Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in the Evercore ISI HealthCONx Conference
02 déc. 2019 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
07 nov. 2019 16h45 HE
|
MacroGenics, Inc.
Rockville, MD, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
06 nov. 2019 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019
06 nov. 2019 09h12 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call
30 oct. 2019 16h05 HE
|
MacroGenics, Inc.
Rockville, MD, Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics, ViewRay, Cadence Bancorp, and ProPetro and Encourages Investors to Contact the Firm
30 oct. 2019 16h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf...
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
25 oct. 2019 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, Oct. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...